Vertex Pharmaceuticals (VRTX)

NASDAQ: VRTX · Real-Time Price · USD

509.64

6.14 (1.22%)

At close: Apr 30, 2025, 3:59 PM

505.05

-0.90%

Pre-market: May 01, 2025, 08:08 AM EDT

1.22% (1D)

Bid	500.55
Market Cap	131.02B
Revenue (ttm)	11.01B
Net Income (ttm)	-535.6M
EPS (ttm)	-2.06
PE Ratio (ttm)	-247.4
Forward PE	24.75
Analyst	Buy

Ask	507.4
Volume	888,064
Avg. Volume (20D)	1,535,226
Open	503.56
Previous Close	503.50
Day's Range	497.34 - 510.77
52-Week Range	377.85 - 519.88
Beta	0.51

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 24, 1991

Employees 6,100

Stock Exchange NASDAQ

Ticker Symbol VRTX

Website https://www.vrtx.com

Full Company Profile

Analyst Forecast

According to 24 analyst ratings, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $526.5, which is an increase of 3.31% from the latest price.

Stock Forecasts

Next Earnings Release

Vertex Pharmaceuticals is scheduled to release its earnings on May 5, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+5.31%

Vertex Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

4 months ago

-11.37%

Vertex Pharmaceuticals shares are trading lower. The company announced results from its Phase 2 study of Suzetrigine.

News

17 hours ago · zacks.com

Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know

Vertex Pharmaceuticals (VRTX) reachead $509.47 at the closing of the latest trading day, reflecting a +1.19% change compared to its last close.

22 hours ago · youtube.com

Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group

Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!

14 hours ago · zacks.com

What Analyst Projections for Key Metrics Reveal About Vertex (VRTX) Q1 Earnings

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua...

2 days ago · seekingalpha.com

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...

2 days ago · seekingalpha.com

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

1 day ago · zacks.com

Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards?

On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).

3 days ago · zacks.com

Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.